Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. by Wright, Peter F et al.
Wright, PF; Connor, RI; Wieland-Alter, WF; Hoen, AG; Boesch,
AW; Ackerman, ME; Oberste, MS; Gast, C; Brickley, EB; Asturias,
EJ; Rttimann, R; Bandyopadhyay, AS (2016) Vaccine-induced mu-
cosal immunity to poliovirus: analysis of cohorts from an open-label,
randomised controlled trial in Latin American infants. The Lancet
infectious diseases, 16 (12). pp. 1377-1384. ISSN 1473-3099 DOI:
https://doi.org/10.1016/S1473-3099(16)30169-4
Downloaded from: http://researchonline.lshtm.ac.uk/4645834/
DOI: 10.1016/S1473-3099(16)30169-4
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
www.thelancet.com/infection   Vol 16   December 2016 1377
Articles
Vaccine-induced mucosal immunity to poliovirus: analysis of 
cohorts from an open-label, randomised controlled trial in 
Latin American infants
Peter F Wright, Ruth I Connor, Wendy F Wieland-Alter, Anne G Hoen, Austin W Boesch, Margaret E Ackerman, M Steven Oberste, Chris Gast, 
Elizabeth B Brickley, Edwin J Asturias, Ricardo Rüttimann, Ananda S Bandyopadhyay
Summary
Background Identiﬁ cation of mechanisms that limit poliovirus replication is crucial for informing decisions aimed at 
global polio eradication. Studies of mucosal immunity induced by oral poliovirus (OPV) or inactivated poliovirus 
(IPV) vaccines and mixed schedules thereof will determine the eﬀ ectiveness of diﬀ erent vaccine strategies to block 
virus shedding. We used samples from a clinical trial of diﬀ erent vaccination schedules to measure intestinal 
immunity as judged by neutralisation of virus and virus-speciﬁ c IgA in stools.
Methods In the FIDEC trial, Latin American infants were randomly assigned to nine groups to assess the eﬃ  cacy of two 
schedules of bivalent OPV (bOPV) and IPV and challenge with monovalent type 2 OPV, and stools samples were collected. 
We selected three groups of particular interest—the bOPV control group (serotypes 1 and 3 at 6, 10, and 14 weeks), the 
trivalent attenuated OPV (tOPV) control group (tOPV at 6, 10, and 14 weeks), and the bOPV–IPV group (bOPV at 6, 10, 
and 14 weeks plus IPV at 14 weeks). Neutralising activity and poliovirus type-speciﬁ c IgA were measured in stool after a 
monovalent OPV type 2 challenge at 18 weeks of age. Mucosal immunity was measured by in-vitro neutralisation of a type 
2 polio pseudovirus (PV2). Neutralisation titres and total and poliovirus-type-speciﬁ c IgG and IgA concentrations in stools 
were assessed in samples collected before challenge and 2 weeks after challenge from all participants.
Findings 210 infants from Guatemala and Dominican Republic were included in this analysis. Of 38 infants tested for 
mucosal antibody in the tOPV group, two were shedding virus 1 week after challenge, compared with 59 of 85 infants 
receiving bOPV (p<0·0001) and 53 of 87 infants receiving bOPV–IPV (p<0·0001). Mucosal type 2 neutralisation and 
type-speciﬁ c IgA were noted primarily in response to tOPV. An inverse correlation was noted between virus shedding 
and both serum type 2 neutralisation at challenge (p<0·0001) and mucosal type 2 neutralisation at challenge (p<0·0001).
Interpretation Mucosal type-2-speciﬁ c antibodies can be measured in stool and develop in response to receipt of OPV 
type 2 either in the primary vaccine series or at challenge. These mucosal antibodies inﬂ uence the amount of virus 
that is shed in an established infection.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
As the spread of poliovirus is progressively constrained 
both geographically and in circulating lineages, crucial 
decisions are being made about future vaccination 
strategies to achieve and sustain the ﬁ nal eradication of 
poliomyelitis.1,2 These plans include elimination of the 
type 2 component of the trivalent oral attenuated 
poliovirus vaccine (tOPV), as recommended by the 
Strategic Advisory Group of Experts on Immunization, 
and replacement with bivalent oral poliovirus vaccine 
(bOPV) accompanied by the introduction of at least one 
dose of inactivated polio vaccine (IPV) into the regimen, 
enhanced environmental surveillance, and the eventual 
elimination of any use of the live oral poliovirus vaccines 
(OPVs) in immunisation programmes. The cessation of 
the use of OPV type 2 and the substitution of at least one 
dose of IPV occurred as planned globally in April and 
May, 2016.
These recommendations, made in 2012, were based on 
expert opinion and the epidemiological situation of 
poliovirus transmission, but no immunogenicity and 
safety data for bOPV–IPV routine immunisation schedules 
compared with tOPV immunisation sche dules—parti-
cularly the eﬀ ects on intestinal immunity against type 2 
Sabin virus—were available to inform them. The IPV and 
OPV both prevent paralytic poliomyelits in the vaccine 
recipient, and both have interrupted transmission, 
although the impact of IPV on transmission has largely 
been reported in developed countries. Mucosal immunity 
is presumed to have a key role in limitation of enteric and 
pharyngeal infection with poliovirus, and hence could be 
crucial in diminishing the eﬃ  ciency of transmission. Yet 
the notion that IPV will be central to maintenance of 
eradication is based on the potential development of 
vaccine-associated paralytic polio in OPV recipients,3 
chronic OPV infection in immunodeﬁ cient vaccine 
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recipients,4 and circulation of vaccine-derived polioviruses.5
The comparative ability of OPV and IPV to induce 
mucosal immunity has been explored since the early days of 
polio research. Ouchterlony double diﬀ usion plates were 
used to show that OPV induces enteric IgA, whereas IPV 
does not, unless preceded by OPV.6,7 The concept that 
mucosal immunity was dependent on previous vaccination 
with OPV was supported by challenging IPV and OPV 
recipients with OPV.8,9 Combination of OPV and IPV to 
broaden immunogenicity was introduced 18 years ago.10 
More recently, investigators in Cuba,11 India,12,13 Bangladesh,14 
Chile,15 and four Latin American countries in the Fighting 
Infectious Diseases in Emerging Countries (FIDEC)16 
consortium have used challenge with either monovalent 
OPV (mOPV) or tOPV as a measure of the immuno genicity 
and protection aﬀ orded by previous immuni sation with 
OPV or IPV, either individually or in combination.
Anticipatory studies of the mechanisms that limit 
poliovirus replication are crucial to inform decisions by 
the Global Polio Eradication Initiative to move from OPV 
to IPV. Studies of mucosal immunity induced by OPV, 
IPV, and mixed schedules will deﬁ ne the best strategy, not 
only for prevention of paralytic disease, but also for the 
true eradication of all circulating poliovirus. The lack of 
deﬁ nitive information in this area was shown in 2013 by 
leaders in the ﬁ eld, who expressed very diverse views on 
the eﬀ ectiveness of IPV in limiting virus replication at 
mucosal sites and thus preventing transmission.17 
Previous studies have yet to link mucosal responses 
measured by current immunological techniques to the 
type of vaccine given or to virus shedding on challenge. To 
address this gap in knowledge, we measured polio-speciﬁ c 
mucosal IgA responses and virus-neutralising capacity of 
stool samples and correlated these ﬁ ndings with vaccine 
regimen and virus shedding on OPV challenge.
Methods
Study design and participants
The FIDEC study (NCT 01831050) was designed to explore 
the safety, immunogenicity, and protective eﬃ  cacy of 
combinations of  IPV and OPV in anticipation of the 
elimination of type 2 OPV from global vaccination use. 
Infants in the study were randomly assigned to nine groups 
to assess the eﬃ  cacy of two schedules of bOPV and IPV 
and challenge with monovalent type 2 OPV. Stool samples 
were collected during the FIDEC trial as reported16 and 
provided to us so that we could analyse mucosal responses. 
Because of the large number of samples collected and the 
complexity of the analyses, stool specimens were 
speciﬁ cally selected from three non-overlapping groups of 
particular scientiﬁ c interest: the bOPV control group, in 
which 210 infants received bOPV (serotypes 1 and 3) at 6, 
10, and 14 weeks, followed by challenge with mOPV type 2 
at 18 weeks; the tOPV control group, in which 100 infants 
received tOPV at 6, 10, and 14 weeks, with mOPV type 2 
challenge at 18 weeks; and the bOPV–IPV group, in which 
210 infants received bOPV at 6, 10, and 14 weeks and one 
dose of the IPV at 14 weeks, with mOPV type 2 challenge at 
18 weeks. Other groups in the parent study that were not 
analysed in ours received either two doses of IPV in 
addition to OPV or were challenged at 40 weeks rather than 
18 weeks with mOPV type 2, or both.16 
The study was approved by the Dartmouth College 
Committee for the Protection of Human Subjects and by 
Research in context
Evidence before this study
We searched PubMed with the term “polio mucosal immunity” for 
articles published in English between Jan 31, 1975, and Dec 31,
2015. We identiﬁ ed several studies in which virus shedding after 
oral challenge was used as a surrogate for mucosal immunity, but 
very few in which investigators attempted to measure IgA speciﬁ c 
antibody in the stool and none in which neutralising antibody in 
the stool was successfully measure and correlated with virus 
recovery on oral poliovirus challenge. 
Added value of this study
We present the ﬁ rst data showing the impact of trivalent 
attenuated oral poliovirus vaccine (tOPV), bivalent oral 
poliovirus vaccine (bOPV), and a combination of bOPV and 
inactivated poliovirus vaccine (IPV) on intestinal immunity 
against type 2 poliovirus when administered according to the 
Expanded Program on Immunization schedule and document 
the eﬀ ect of that immunity on subsequent challenge with the 
proposed outbreak response tool of the future, monovalent 
oral poliovirus vaccine (mOPV) type 2. Immunity is measured 
by restriction of virus shedding, neutralisation of virus in the 
stool, and mOPV type 2 IgA speciﬁ c antibody. The correlations 
of each with the other strengthens the concept that we now 
have tools to measure mucosal immunity and predict the 
eﬀ ectiveness of a vaccine regimen in limiting outbreaks as we 
approach polio eradication.
Implications of the available evidence
Our novel data have direct and immediate global policy 
implications and point to the unique ability of tOPV to stimulate 
mucosal immunity, the dissociation of serum and mucosal 
antibody responses, and the crucial role of mucosal immunity in 
preventing infection on an mOPV type 2 challenge. They provide 
support for the global withdrawal of type-2-containing oral 
poliovirus vaccines to eliminate the only source of paralytic 
disease caused by this serotype, and show that, although IPV is 
highly protective against paralytic disease in the individual 
vaccinee, it has only a small eﬀ ect on subsequent virus shedding 
and thus could allow a continued train of transmission. Our data 
will help national, regional, and global policy makers to develop 
public health strategies to achieve and sustain polio eradication 
in the near term and long term.
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the FIDEC ethical review process. Provision had been 
made in the initial consent for future studies and it was 
judged unnecessary to reconsent the volunteers. 
Procedures
The FIDEC study was implemented in four countries 
(Colombia, Dominican Republic, Guatemala, and 
Panama). We determined that analysis of all samples from 
two of these countries—Dominican Republic and 
Guatemala—would yield statistically meaningful data for 
our study. Because limited inter-country diﬀ erences were 
noted, results from the two countries were pooled for all 
data analyses.
Stool samples (5–10 g) were collected and frozen in 
aliquots in the country of origin. Samples were then 
shipped frozen to the Geisel School of Medicine at 
Dartmouth (Hanover, NH, USA). Assays quantifying 
virus neutralisation titres and IgA concentrations in stools 
were done at Dartmouth as previously reported.18,19 
Mucosal immunity was measured by in-vitro 
neutralisation of a type 2 polio pseudovirus (PV2). 
Neutralisation titres and total and polio-type-speciﬁ c IgG 
and IgA concentrations in stools were assessed in samples 
collected before challenge and 2 weeks after challenge 
from all subjects. The same measurements were done on 
samples collected weekly for the ﬁ rst 4 weeks after 
challenge from 49 randomly chosen parti cipants by the 
Dartmouth team (before any know ledge of group 
allocation). Serum neutralisation titres before challenge 
and a week later, and virus shedding weekly after 
challenge, were measured at the Polio and Picornavirus 
Laboratory Branch of the Centers for Disease Control 
and Prevention (Atlanta, GA, USA). Vaccine group 
assignment, serum neutralisation titres, and virus 
shedding were unblinded to the Dartmouth study team 
after completion of sample testing and data sharing.
Statistical analyses
Diﬀ erences in the proportions of children with virus 
shedding and with measurable PV2 mucosal neutra-
lisation were compared across the three vaccine regimen 
groups with Pearson’s χ² test. We used ANOVA to 
compare the geometric means of observed virus shedding, 
stool and serum neutralisation titres, and mucosal IgA 
concentrations across the three groups. Diﬀ erences 
between pairs of groups and between visits within each 
group were compared with Tukey’s honest signiﬁ cant 
diﬀ erence method—a simultaneous com parison of all 
pairwise means that identiﬁ es diﬀ erences between two 
means that are greater than the expected SE and is robust 
when sample sizes are unequal between groups. Dif-
ferences were deemed signiﬁ cant and p values reported 
when p was less than 0·05.
We used Spearman’s rank correlation coeﬃ  cients to 
examine correlations between shedding 1 week after type 2 
mOPV challenge and poliovirus-type-speciﬁ c serum and 
stool neutralisation titres and mucosal IgA concentrations 
at the time of challenge. We plotted the median (IQR) con-
cen trations of each y variable against the mean for each 
third of the x variables, which allowed us to assess the shape 
of any correlation without assuming linearity a priori.
Role of the funding source
ASB is an employee of the study funder, and was involved 
in study design, data interpretation, and writing of the 
report. The funder had no role in data collection. All 
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Figure 1: Poliovirus shedding in stools 1 week after mOPV type 2 challenge
p<0·0001 after bOPV, tOPV, or bOPV–IPV at 6, 10, and 14 weeks. mOPV type 2 challenge was at 18 weeks. 
mOPV=monovalent oral poliovirus vaccine. bOPV=bivalent oral poliovirus vaccine. tOPV=trivalent attenuated oral 
poliovirus vaccine. IPV=inactivated poliovirus vaccine. NS=not signiﬁ cant.
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Figure 2: Type 2 polio pseudovirus neutralising titre measured in stools at the time of mOPV type 2 challenge
p<0·0001 after bOPV, tOPV or bOPV–IPV at 6, 10, and 14 weeks. mOPV type 2 challenge was at 18 weeks. 
mOPV=monovalent oral poliovirus vaccine. bOPV=bivalent oral poliovirus vaccine. tOPV=trivalent attenuated oral 
poliovirus vaccine. IPV=inactivated poliovirus vaccine. 
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authors had full access to all the data in the study and share 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
In total, 586 samples were analysed from 210 infants 
given bOPV (n=85), tOPV (n=38), or bOPV–IPV (n=87), 
which represented approximately 40% of the children in 
each group. Virus shedding was diminished 1 week after 
mOPV type 2 challenge by previous receipt of a vaccine 
containing homologous live type 2 in the immunisation 
schedule (ﬁ gure 1). Infants in the tOPV group 
demonstrated very limited virus shedding (two [5%] of 
38 infants) compared with infants receiving bOPV 
(59 [69%] of 85) or bOPV–IPV (53 [61%] of 87; 
χ² [1, n=123]=43·2, p<0·0001 for tOPV group vs bOPV 
group; χ² [1, N=125]=33·3, p<0·0001 for tOPV group vs 
bOPV–IPV group). The full pattern of shedding is 
reported separately.16
Mucosal immunity at the time of the mOPV type 2 
challenge was signiﬁ cantly associated with previous 
receipt of a vaccine containing the OPV type 2 com-
ponent—ie, tOPV (ﬁ gure 2). 14 (17%) of 82 individuals 
given bOPV also demonstrated mucosal PV2 
neutralisation. One dose of IPV at 14 weeks (ie, in the 
bOPV–IPV group) was associated with measurable PV2 
mucosal neutralisation in 21 (26%) of 82 infants, 
compared with 35 (42%) of 84 infants given bOPV (χ² 
[1, N=166]=4·79, p=0·03; ﬁ gure 2). However, the 
additional dose of IPV had no signiﬁ cant eﬀ ect on the 
level of virus shedding compared with bOPV only 
(ﬁ gure 1). At the time of mOPV type 2 challenge, type 1 
polio pseudovirus neutralisation titres were similar in 
the three groups (data not shown).
Type-2-speciﬁ c IgA concentrations measured in stool at 
the time of mOPV type 2 challenge were signiﬁ cantly 
higher in infants given tOPV than in those receiving 
bOPV or bOPV–IPV (ﬁ gure 3). Total IgG concentrations 
in the stool specimens were much lower than those of 
IgA; polio-strain-speciﬁ c IgG antibodies were rarely 
detected (data not shown). Type-2-speciﬁ c serum 
neutralisation titres were signiﬁ cantly higher in infants 
who received a homologous type 2 vaccine (ie, those in 
the tOPV and bOPV–IPV groups) than in those who did 
not (ﬁ gure 4).
Mucosal neutralising activity to PV2 developed rapidly 
after administration of the mOPV type 2 challenge in the 
bOPV and bOPV–IPV groups, reaching the levels of the 
tOPV group by 2 weeks after challenge (ﬁ gure 5A). Mean 
IgA concentrations also increased in stool by 3–4 weeks 
after challenge in the bOPV and bOPV–IPV groups 
(ﬁ gure 5B). By comparison, the vaccine regimen did not 
aﬀ ect mucosal type-1-speciﬁ c or type-3-speciﬁ c IgA 
concentrations at the time of challenge, and these 
concentrations did not rise signiﬁ cantly after mOPV type 
2 challenge (data not shown).
Serum was obtained immediately before challenge and 
1 week later under the assumption that this practice 
would capture a rapid anamnestic antibody response to 
vaccine priming. Serum neutralisation titres determined 
for the two available timepoints showed no signiﬁ cant 
increase 1 week after challenge in the bOPV and 
bOPV–IPV groups (ﬁ gure 5C). A comparison of both the 
mucosal and serum neutralisation titres 1 week after 
mOPV type 2 challenge showed equivalent responses in 
the bOPV and bOPV–IPV groups (ﬁ gure 5A, 5C).
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Figure 3: IgA antibody concentrations measured in stools by Luminex assay after mOPV type 2 challenge
Normalised IgA concentration is the normalised polio type 2 speciﬁ c IgA in stool relative to a total IgA serum 
standard IgA. p=0·0007 after bOPV, tOPV or bOPV–IPV at 6, 10, and 14 weeks. mOPV type 2 challenge was at 
18 weeks. mOPV=monovalent oral poliovirus vaccine. bOPV=bivalent oral poliovirus vaccine. tOPV=trivalent 
attenuated oral poliovirus vaccine. IPV=inactivated poliovirus vaccine. 
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Figure 4: Type-2-speciﬁ c neutralising titre in serum after mOPV type 2 challenge
p<0·0001 after bOPV, tOPV, or bOPV–IPV at 6, 10, and 14 weeks. mOPV type 2 challenge was at 18 weeks. 
mOPV=monovalent oral poliovirus vaccine. bOPV=bivalent oral poliovirus vaccine. tOPV=trivalent attenuated oral 
poliovirus vaccine. IPV=inactivated poliovirus vaccine. 
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Virus shedding was restricted 1 week after mOPV type 
2 challenge in the tOPV group, which had received OPV 
type 2 as a component of the trivalent vaccine, compared 
with that in the bOPV and bOPV–IPV groups, neither of 
which had received OPV type 2 (ﬁ gure 1; p<0·0001 for both). 
Similarly, signiﬁ cantly higher mucosal neutralising 
responses to PV2 were noted in tOPV recipients at the 
time of mOVP type 2 challenge than were noted in those 
in the bOPV and bOPV–IPV groups (ﬁ gure 2).
Separate analyses of the distribution of the type-2-
speciﬁ c serum and stool neutralisation responses at the 
time of mOPV type 2 challenge demonstrated a 
signiﬁ cant relation between the heights of each response 
with the subsequent reduction in virus shedding 1 week 
after challenge (ﬁ gures 6A, 6B). Concentrations of type-2-
speciﬁ c IgA measured at challenge did not correlate with 
subsequent virus shedding 1 week later (ﬁ gure 6C). 
A comparison of PV2-speciﬁ c mucosal neutralisation 
titres with IgA concentrations in stools from the tOPV 
recipients at the time of challenge was signiﬁ cant 
(p=0·043), with a weak correlation (r=0·33). Notably, by 
2 weeks after mOPV type 2 challenge—when neutralising 
PV2-speciﬁ c antibody responses in stool were 
signiﬁ cantly increased in the bOPV and bOPV–IPV 
groups compared with those at time of challenge 
(ﬁ gure 5A)—the correlation of mucosal neutralisation 
with type-2-speciﬁ c IgA concentrations in stool was 
strong (ﬁ gure 7B).
In infants shedding virus after mOPV type 2 challenge, 
we noted a signiﬁ cant inverse correlation between the 
height of the mucosal response, as measured by both 
virus neutralising activity and IgA concentrations in 
stool, and the amount of virus concurrently shed 2 weeks 
after challenge (ﬁ gure 7B). A correlation of virus 
shedding with mucosal IgA was not noted (ﬁ gure 7C).
Discussion
Our results suggest that mucosal neutralising type-2-
speciﬁ c antibody, generated by previous serotype-speciﬁ c 
OPV exposure, highly corresponds with resistance to 
challenge with mOPV type 2. Although type-2-speciﬁ c 
serum neutralising antibody also in ﬂ uenced the initial 
replication of mOPV type 2 after challenge, further 
ampliﬁ cation of this response by inclusion of a dose of 
IPV in the immunisation regimen (ie, in the bOPV–IPV 
group) did not further reduce virus recovery. Restriction 
of virus shedding after mOPV type 2 challenge was 
linked to previous receipt of homotypic OPV (tOPV). 
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Figure 5: Mean PV2-speciﬁ c neutralisation titres in stool (A), mean 
concentrations of PV2-speciﬁ c mucosal IgA in stool (B), and mean 
type-2-speciﬁ c serum neutralisation titres (C) at the time of mOPV type 2 
challenge and weekly thereafter
Mucosal IgA concentration is mucosal type 2 speciﬁ c IgA in stool relative to a 
total IgA serum standard. PV2=type 2 polio pseudovirus. mOPV=monovalent 
oral poliovirus vaccine. bOPV=bivalent oral poliovirus vaccine. tOPV=trivalent 
attenuated oral poliovirus vaccine. IPV=inactivated poliovirus vaccine. *Indicates 
a signiﬁ cant increase in titre compared with that at the time of challenge.
Articles
1382 www.thelancet.com/infection   Vol 16   December 2016
Additionally, little if any immunity to type 2 mOPV was 
induced by receipt of heterotypic bOPV. Although 
unlikely, resistance to mOPV type 2 challenge could be 
due to induction of some other type of protective 
immunity unrelated or additional to the observed 
mucosal and serum neutralisation responses. Because 
the number of infants in the tOPV group who shed virus 
after challenge was quite small, we were unable to 
rigorously implicate mucosal antibody as the key 
protective factor within that group. In general, discerning 
the relative contribution of mucosal or serum 
neutralisation responses to the recorded restriction of 
virus shedding was complicated by the limited number 
of infants shedding virus after immunisation with tOPV; 
confounding serum and mucosal antibody responses 
that were not attributable to vaccine receipt in the trial 
and were noted in infants from all groups; and a general 
concordance of the mucosal and serum neutralising 
responses after immunisation with tOPV.
Furthermore, we conclude that serum neutralising 
antibody, the traditional measure of vaccine-induced 
immunity, is a limited determinant of virus replication in 
the intestinal tract. This observation is crucial to decisions 
about future approaches to elimination of poliovirus 
circulation and sustainment of a polio-free world. The 
experience in Israel, where sustained circulation of wild-
type polio occurred in a population highly immunised 
with IPV,20 provides further evidence of the importance 
of adopting an endgame vaccine regimen for the interim 
that also induces mucosal immunity.
Together with our preceding study,18 in this study we 
establish a unique method to measure strain-speciﬁ c 
mucosal antibody responses to poliovirus that reveals 
functionality (virus neutralisation) at very high titres 
(often ≥512) equivalent to those measured in serum. 
Previous attempts to measure mucosal immunity have 
largely focused on measurements of binding antibody, 
primarily of the IgA class. Luminex provides a state-of-
the-art platform for polio-speciﬁ c IgA determination. 
Substantial diﬃ  culties have also been encountered in 
development of reproducible assays to assess virus 
neutralisation mediated by respiratory, genital, or enteric 
specimens. Aside from the recognised complications of 
sample variability during collection, processing, and 
assaying, measurement of functional activity in biological 
assays is fraught with challenges associated with cellular 
toxicity or cell culture contamination by the specimen, or 
both. Most of these shortcomings are subverted by the 
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Figure 6: Relation between peak type-2-speciﬁ c neutralisation titres in 
serum (A), peak type-2-speciﬁ c neutralisation titres in stool (B), and 
type-2-speciﬁ c mucosal IgA concentrations (C) at the time of mOPV type 2 
challenge, and virus shedding 1 week later
Data in each panel represent combined responses for all three vaccine groups. 
Black squares and bars indicate the median (IQR) of virus shedding within thirds 
of antibody responses plotted against the mean of the antibody responses 
within each third. mOPV=monovalent oral poliovirus vaccine. TCID50=50% tissue 
culture infective dose.
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rapid readout of the polio pseudovirus assay, which 
provides a sensitive and reproducible means of assessing 
neutralisation after a single cycle of virus replication.18
Several questions remain unanswered. First, what is 
the origin of the serum and mucosal neutralising 
responses seen in the bOPV group before OPV type 2 
challenge, which theoretically had not yet received any 
type 2 vaccine? Serum responses could indicate residual 
maternal antibody or antibody acquired during 
intercurrent infection, although eﬀ orts were made to 
avoid any secondary exposure to vaccine virus in the 
family setting. Mucosal antibody responses might also 
reﬂ ect variation in sample collection, storage, or residual 
maternal breast milk antibody. Second, what mediates 
the early neutralising response noted on challenge? IgA 
is assumed to be the major mediator of mucosal 
immunity.21 If so, why was there not a better correlation 
between the height of mucosal neutralisation and IgA 
concentrations at challenge and the amount of virus 
shedding 1 week later? In determining virus titre, the 
samples were frozen on collection and treated with 
chloroform immediately after thawing. We have shown 
that chloroform rapidly inactivates antibody. Thus 
neutralisation has little opportunity to occur in the 
limited timeframe between evacuation and sample 
processing. With respiratory syncytial virus, mucosal 
antibody was found bound to cell-associated virus in 
secretions and only later were investigators able to detect 
free antibody.22 The poorly deﬁ ned site or sites of 
replication of poliovirus in the enteric tract (eg, Peyer’s 
patches) could make the virus inaccessible to antibody 
secreted into the intestinal lumen.23 Furthermore, we 
would conclude that the induction of immunity noted 
1 week after challenge is not necessarily indicative of 
priming, because it was reported in children who were 
undergoing their initial exposure to type 2 vaccine. 
Finally, the duration of mucosal immunity is unknown, 
but we suspect it to be shorter than that of serum 
antibody, and thus the protection recorded almost 
certainly will wane.24 In this study, we could not address 
duration or the concept that previous OPV mucosal 
immunity is boosted by IPV.25
In summary, another tool has been added to assess-
ments of immunity after receipt of polio vaccines. Our 
ﬁ ndings move beyond the initial observation that OPV is 
a much better mucosal immunogen than IPV, as 
evidenced by greater inhibition of virus replication upon 
challenge, and show a mechanism by which this anti-
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(B), and mucosal IgA concentrations and poliovirus shedding (C) 2 weeks 
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viral activity might occur. In deﬁ ning a mechanism for 
measuring mucosal immunity for polio, there is a 
mandate to extend these observations and apply these 
ﬁ ndings to other live virus vaccines that are either in 
clinical use (eg, inﬂ uenza, rotavirus) or actively under 
development (eg, respiratory syncytial virus).
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